Dylan Gagler
16 Papers
Dylan Gagler is an academic researcher. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has co-authored 7 publications.
Chat about Author
Papers
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
Francesco Lauria,Eileen M Boyle,David Coffey,Kylee H Maclachlan,Dylan Gagler,Benjamin Diamond,Hussein Ghamlouch,Patrick Blaney,Bachisio Ziccheddu,Anthony Cirrincione,Monika Chojnacka,Yubao Wang,Ariel Siegel,James E. Hoffman,Dickran Kazandjian,Hani Hassoun,Emily Guzman,Sham Mailankody,Urvi A Shah,Carlyn Tan,Malin Hultcrantz,Michael Scordo,Gunjan L. Shah,Heather Landau,David J. Chung,Sergio A. Giralt,Yanming Zhang,Arnaldo Arbini,Qi Gao,Mikhail Roshal,Ahmet Dogan,Alexander M. Lesokhin,Faith E. Davies,Saad Usmani,Neha Korde,Gareth J. Morgan,Ola Landgren +36 more
TL;DR: Overall, this study provides strong evidence of a complex interplay between tumor cells and the immune microenvironment that is predictive of clinical outcome and depth of treatment response in patients with newly diagnosed multiple myeloma treated with highly effective combinations containing anti-CD38 antibodies.
18
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Anthony Cirrincione,Alexandra M Poos,Bachisio Ziccheddu,Marcella Kaddoura,Marc-Andrea Baertsch,Kylee H Maclachlan,Monika Chojnacka,Benjamin Diamond,Lukas John,Philipp Reichert,Stefanie Huhn,Patrick Blaney,Dylan Gagler,Karsten Rippe,Yanming Zhang,Ahmet Dogan,Alexander M. Lesokhin,Faith E. Davies,Hartmut Goldschmidt,Roland Fenk,Katja C Weisel,Elias K. Mai,Neha Korde,Gareth J. Morgan,Saad Z Usmani,O. Landgren,Marc S. Raab,Niels Weinhold,Francesco Maura +28 more
TL;DR: Pre- and post-gain deletions are novel driver mechanisms in multiple myeloma, impacting tumor suppressor and oncogenes.
4
Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
Francesco Lauria,Eileen M Boyle,David C. Coffey,Kylee H Maclachlan,Benjamin Diamond,Patrick Blaney,Dylan Gagler,Bachisio Ziccheddu,Hussein Ghamlouch,Yubao Wang,James E. Hoffman,Dickran Kazandjian,Hani Hassoun,Emily Guzman,Sham Mailankody,Urvi A Shah,Carlyn Rose C. Tan,Malin Hultcrantz,Michael Scordo,Gunjan L. Shah,Heather Landau,David J. Chung,Sergio Giralt,Yanming Zhang,Ahmet Dogan,Alexander M. Lesokhin,Dennis Verducci,Faith E. Davies,Saad Usmani,Neha Korde,Gareth J. Morgan,Ola Landgren +31 more
3
Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation
Patrick Blaney,Brian Walker,Aneta Mikulasova,Dylan Gagler,Bachisio Ziccheddu,Benjamin Diamond,Yubao Wang,Liming Hou,Sanxiong Liu,Alexandra M Poos,Anthony Cirrincione,Kylee H Maclachlan,Elias K. Mai,Hartmut Goldschmidt,Saad Usmani,Marc S. Raab,Niels Weinhold,O. Landgren,Faith E. Davies,Francesco Lauria,Gareth J. Morgan +20 more
TL;DR: The non-coding genome is characterized to gain significant insight into the role of mutations in gene regulatory elements in the etiology of multiple myeloma (MM) and to models of how it develops.
3
Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma
Eileen M Boyle,Patrick Blaney,James H. Stoeckle,Yubao Wang,Hussein Ghamlouch,Avital Tenenbaum,Ariel Siegel,Xiaoyi Chen,Gaurav Varma,David Kaminetzsky,Marc Braunstein,Lydia Montes,Jill Corre,Even H Rustad,Ola Landgren,Francesco Lauria,Benedetto Bruno,Aristotelis Tsirigos,Brian A Walker,Faith E. Davies,Dylan Gagler,Gareth J. Morgan +21 more
TL;DR: In this paper , the structural changes seen at the 1q level and integrated with expression and clinical data to identify potential drivers and gain insight into progression mechanisms were analyzed using GISTIC 2.0 and PFC.
1